467 related articles for article (PubMed ID: 28157429)
1. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
[TBL] [Abstract][Full Text] [Related]
2. Development of Core-Fucose-Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies.
Kaneko MK; Ohishi T; Nakamura T; Inoue H; Takei J; Sano M; Asano T; Sayama Y; Hosono H; Suzuki H; Kawada M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):167-174. PubMed ID: 33085938
[TBL] [Abstract][Full Text] [Related]
3. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
[TBL] [Abstract][Full Text] [Related]
4. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.
Kaneko MK; Kunita A; Abe S; Tsujimoto Y; Fukayama M; Goto K; Sawa Y; Nishioka Y; Kato Y
Cancer Sci; 2012 Nov; 103(11):1913-9. PubMed ID: 22816430
[TBL] [Abstract][Full Text] [Related]
5. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.
Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK
Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352
[TBL] [Abstract][Full Text] [Related]
6. Establishment of P38Bf, a Core-Fucose-Deficient Mouse-Canine Chimeric Antibody Against Dog Podoplanin.
Kato Y; Mizuno T; Yamada S; Nakamura T; Itai S; Yanaka M; Sano M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2018 Nov; 37(5):218-223. PubMed ID: 30362926
[TBL] [Abstract][Full Text] [Related]
7. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.
Kaneko MK; Yamada S; Nakamura T; Abe S; Nishioka Y; Kunita A; Fukayama M; Fujii Y; Ogasawara S; Kato Y
Cancer Med; 2017 Apr; 6(4):768-777. PubMed ID: 28332312
[TBL] [Abstract][Full Text] [Related]
10. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2.
Ogasawara S; Kaneko MK; Price JE; Kato Y
Hybridoma (Larchmt); 2008 Aug; 27(4):259-67. PubMed ID: 18707544
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.
Kato Y; Kaneko MK; Kunita A; Ito H; Kameyama A; Ogasawara S; Matsuura N; Hasegawa Y; Suzuki-Inoue K; Inoue O; Ozaki Y; Narimatsu H
Cancer Sci; 2008 Jan; 99(1):54-61. PubMed ID: 17944973
[TBL] [Abstract][Full Text] [Related]
12. Establishment of Mouse Monoclonal Antibody LpMab-13 Against Human Podoplanin.
Ogasawara S; Kaneko MK; Honma R; Oki H; Fujii Y; Takagi M; Suzuki H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):155-62. PubMed ID: 27328060
[TBL] [Abstract][Full Text] [Related]
13. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.
Abe S; Morita Y; Kaneko MK; Hanibuchi M; Tsujimoto Y; Goto H; Kakiuchi S; Aono Y; Huang J; Sato S; Kishuku M; Taniguchi Y; Azuma M; Kawazoe K; Sekido Y; Yano S; Akiyama S; Sone S; Minakuchi K; Kato Y; Nishioka Y
J Immunol; 2013 Jun; 190(12):6239-49. PubMed ID: 23690472
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain.
Kato Y; Kaneko MK; Kuno A; Uchiyama N; Amano K; Chiba Y; Hasegawa Y; Hirabayashi J; Narimatsu H; Mishima K; Osawa M
Biochem Biophys Res Commun; 2006 Nov; 349(4):1301-7. PubMed ID: 16979138
[TBL] [Abstract][Full Text] [Related]
15. Establishment of Monoclonal Antibody PMab-202 Against Horse Podoplanin.
Furusawa Y; Yamada S; Itai S; Sano M; Nakamura T; Yanaka M; Handa S; Mizuno T; Maeda K; Fukui M; Harada H; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2018 Nov; 37(5):233-237. PubMed ID: 30362932
[TBL] [Abstract][Full Text] [Related]
16. PMab-52: Specific and Sensitive Monoclonal Antibody Against Cat Podoplanin for Immunohistochemistry.
Yamada S; Itai S; Nakamura T; Yanaka M; Saidoh N; Chang YW; Handa S; Harada H; Kagawa Y; Ichii O; Konnai S; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Oct; 36(5):224-230. PubMed ID: 28737447
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal Antibody LpMab-9 Recognizes O-glycosylated N-Terminus of Human Podoplanin.
Kaneko MK; Oki H; Hozumi Y; Liu X; Ogasawara S; Takagi M; Goto K; Kato Y
Monoclon Antib Immunodiagn Immunother; 2015 Oct; 34(5):310-7. PubMed ID: 26492618
[TBL] [Abstract][Full Text] [Related]
18. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis.
Sekiguchi T; Takemoto A; Takagi S; Takatori K; Sato S; Takami M; Fujita N
Oncotarget; 2016 Jan; 7(4):3934-46. PubMed ID: 26684030
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.
Kato Y; Vaidyanathan G; Kaneko MK; Mishima K; Srivastava N; Chandramohan V; Pegram C; Keir ST; Kuan CT; Bigner DD; Zalutsky MR
Nucl Med Biol; 2010 Oct; 37(7):785-94. PubMed ID: 20870153
[TBL] [Abstract][Full Text] [Related]
20. The mouse-canine chimeric anti-dog podoplanin antibody P38B exerts antitumor activity in mouse xenograft models.
Kato Y; Ohishi T; Kawada M; Maekawa N; Konnai S; Itai S; Yamada S; Kaneko MK
Biochem Biophys Rep; 2019 Mar; 17():23-26. PubMed ID: 30519645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
